Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Recent data suggest that aspirin may be effective for reducing cancer mortality.
To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention.
We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective.
Cost per quality-adjusted life year (QALY) gained.
When no effect on cancer mortality was included, aspirin had a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) risk; at 2.5 % risk or below, no treatment was favored. When we included a reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk.
Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.
- Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. CrossRef
- Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: asex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13. Erratum in: JAMA. 2006 May 3;295(17):2002. PubMed PMID:16418466. CrossRef
- Hernandez-Diaz S, Garcia Rodriquez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22. CrossRef
- De Berardis G, Lucisano G, D’Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307(21):2286–94. CrossRef
- US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396–404. CrossRef
- Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162(1):115–24.e2. Review. PubMed PMID: 21742097. CrossRef
- Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124(7):621–9. Epub 2011 May 17. PubMed PMID: 21592450. CrossRef
- Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85(3):265–271. CrossRef
- Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209–16. Epub 2012 Jan 9. Review. PubMed PMID: 22231610. CrossRef
- Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144(5):326–36. CrossRef
- Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011;171(3):218–25. PubMed PMID: 21325111; PubMed Central PMCID: PMC3137269. CrossRef
- Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875–83. Epub 2008 May 27. PubMed PMID: 18506010. CrossRef
- Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41. Epub 2010 Dec 6. PubMed PMID: 21144578. CrossRef
- Chan AT, Cook NR. Are we ready to recommend aspirin for cancer prevention? Lancet. 2012;379(9826):1569–71. Epub 2012 Mar 21. PubMed PMID: 22440945. CrossRef
- Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007;167(3):290–5. CrossRef
- Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S. The natural history of prevalent ischaemic heart disease in middleaged men. Eur Heart J. 2000;21(131):1052–62. CrossRef
- Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24(6):796–800. CrossRef
- Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(part 2):293–8. CrossRef
- Kung HC, Hoyert DL, Xu JQ, Murphy SL. Deaths: Final Data for 2005. National Vital Statistics Reports; vol 56 no 10. Hyattsville, MD: National Center for Health Statistics; 2008.
- Surveillance, Epidemiology, and End Results Program. SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009. Available at: www.seer.cancer.gov. Accessed on September 8, 2011.
- van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98(7):1494–9. CrossRef
- Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom: Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995;311:222–226. CrossRef
- Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12. Epub 2012 Mar 21. Review. PubMed PMID: 22440946. CrossRef
- He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke. JAMA. 1998;280(22):1930–5. CrossRef
- LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340–6. CrossRef
- Meara E, White C, Cutler DM. Trends in medical spending by age, 1963-2000. Health Aff (Millwood). 2004;23(4):176–183. CrossRef
- Lubitz J, Cai L, Kramarow E, Lentzner H. Health, life expectancy, and health care spending among the elderly. N Engl J Med. 2003;349(11):1048–1055. CrossRef
- U.S. Department of Labor, U.S. Bureau of Labor Statistics, US city average, not seasonally adjusted medical care. http://data.bls.gov/PDQ/outside.jsp?survey=cu. Accessed February 2012.
- Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 Patients. Am J Med. 2012 Jun 27.[Epub ahead of print] PubMed PMID: 22748400.
- Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med. 2002;136(2):61–172. CrossRef
- Straube S, Tramèr MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 2009;9:41. CrossRef
- www.Walgreens.com, accessed 9Sep11.
- Ingenix, Inc. The Essential RBRVS (2012): A comprehensive listing of RBRVS values for CPT and HCPCS Codes. St. Anthony Publishing, 2012.
- HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/HCUPnet/ Accessed 7Mar2012.
- Friedman B, La Mare J, Andrews R, McKenzie DH. Assuming an average cost to charge ratio of 0.5: practical options for estimating cost of hospital inpatient stays. J Health Care Finance. 2002;29(1):1–13.
- Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81(9):1110–5. CrossRef
- Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2011;123(4):e18–e209. CrossRef
- Leibson CL, Hu T, Brown RD, Hass SL, O’Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after first stroke: A population-based study. Neurology. 1996;46(3):1–13.
- Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008;24(2):461–468. CrossRef
- Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med. 1998;13(12):824–35. CrossRef
- Nease RF, Kneeland T, O’Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA. 1995;273(5):1185–90. CrossRef
- Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, et al. Stroke after thrombolysis: mortaltiy and functional outcomes in the GUSTO-I trial. Circulation. 1995;92(10):2811–8. CrossRef
- Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13(2):161–5. CrossRef
- Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men
Journal of General Internal Medicine
Volume 28, Issue 11 , pp 1483-1491
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- cancer mortality
- coronary heart disease
- guideline-based intervention
- primary prevention
- Industry Sectors
- Author Affiliations
- 1. Cecil Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC, USA
- 2. Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA
- 5. Department of Medicine, University of North California, 5045 Old Clinic Building UNC Hospital, Chapel Hill, NC, 27599-7110, USA
- 3. RTI Health Solutions, RTI International Research Triangle Park, RTP, NC, USA
- 4. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA